Total
0
Shares
Respiri (ASX:RSH) teams up with Pharmacy Guild to educate pharmacists on asthma management
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management
  • The Pharmacy Guild represents over 5700 community pharmacies across the country
  • The asthma management will be an online training course with Guild Learning and Development
  • The program will also be supported by Respiri's wheezo's, which monitor asthma wheezing
  • On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each

eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management.

The Pharmacy Guild represents over 5700 community pharmacies across the country.

The agreement is for two years and the education program will be with Guild Learning and Development (GuildEd), which is a learning destination for Australian pharmacists, pharmacy assistants and interns.

The education program is an online training course for asthma patient management, in particular children. This will inform pharmacists to better help patients diagnosed with asthma.

The program will also be supported by Respiri's wheezo's, which monitor asthma wheezing.

Respiri CEO Marjan Mikel says with over 65,000 pharmacists practising in Australia, the company understands the importance of helping educate pharmacists.

"Respiri understands their [pharmacists] importance in helping patients with asthma better manage their condition ensuring a better health outcome and quality of life and the critical need for Respiri to build relationships with these key healthcare professionals to help them better understand how wheezo will help drive these patient outcomes," he said.

"By educating pharmacists, who are an important intermediary between an asthmatic patient and their doctor and who already sell a range of asthmatic devices within the pharmacy setting, we see them as a critical determinant in building sales momentum and significant growth within this important channel," he added.

On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each.

RSH by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon - The Market Herald

" Little Green Pharma (ASX:LGP) pursues global expansion over June quarter

Little Green Pharma (LGP) celebrated backing from Gina Rhineheart and a major medicinal cannabis facility purchase over the June quarter but noted subdued

" Chimeric Therapeutics (ASX:CHM) obtains licence for solid tumour cell therapy

Chimeric Therapeutics (CHM) has obtained the exclusive licence to a novel treatment for solid tumours from the University of Pennsylvania.  
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) strikes UK distribution deal for COVID-19 test tech

Surface chemistry company AnteoTech (ADO) has struck its first European distribution deal for its EuGeni rapid diagnostic test (RDT) technology.
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) gets green light for US patent

Medlab Clinical (MDC) has been issued with a notice of allowance by the United States Patent Office (USPTO) regarding a patent for its